Close Menu

SAN FRANCISCO — Fledgling high-content screening company Cellumen has landed its first customer as part of its hybrid business strategy to be an HCS service provider as well as a reagent provider, Inside Bioassays has learned.

In an interview conducted at Cambridge Healthtech Institute’s High-Content Analysis conference held here two weeks ago, Lansing Taylor, Cellumen’s CEO, said that Cellumen has forged a partnership with an undisclosed biotech that will serve as a litmus test for its proposed dual business strategy.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.